Department of Laboratory Medicine, Nagasaki University School of Medicine, 1-7-1 Sakamoto, Nagasaki 852-8102, Japan.
J Infect Chemother. 2011 Jun;17(3):318-21. doi: 10.1007/s10156-010-0166-1. Epub 2010 Oct 23.
Doripenem is a carbapenem antibiotic with broad-spectrum coverage of gram-positive and gram-negative bacteria, including Pseudomonas aeruginosa, and is considered to be as effective as meropenem. The in vivo activity of doripenem was thus compared with that of meropenem in a chronic lower respiratory P. aeruginosa infection mouse model. The number of viable bacteria in the lungs of mice after treatment with doripenem, meropenem, and saline was 2.01 ± 0.69, 2.03 ± 0.48, and 3.90 ± 1.40 log₁₀ CFU/lung, respectively. The number of viable bacteria in the lungs of mice treated with doripenem and meropenem was significantly lower than that in lungs of controls. Histopathological examination of lung specimens from the control group revealed promotion of the inflammatory response in chronic bronchial infection. However, the groups treated with doripenem and meropenem showed weaker inflammatory responses. These results suggest that doripenem treatment is effective against chronic airway infection with P. aeruginosa.
多利培南是一种碳青霉烯类抗生素，对革兰阳性和革兰阴性菌具有广泛的覆盖范围，包括铜绿假单胞菌，并被认为与美罗培南一样有效。因此，在慢性下呼吸道铜绿假单胞菌感染小鼠模型中比较了多利培南和美罗培南的体内活性。多利培南、美罗培南和生理盐水治疗后小鼠肺部的活菌数分别为 2.01±0.69、2.03±0.48 和 3.90±1.40 log₁₀ CFU/肺。多利培南和美罗培南治疗组小鼠肺部的活菌数明显低于对照组。对照组肺标本的组织病理学检查显示慢性支气管感染中炎症反应增强。然而，多利培南和美罗培南治疗组的炎症反应较弱。这些结果表明，多利培南治疗对慢性气道铜绿假单胞菌感染有效。
